"Drug Repositioning" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The deliberate and methodical practice of finding new applications for existing drugs.
| Descriptor ID |
D058492
|
| MeSH Number(s) |
E05.295.875
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Drug Repositioning".
Below are MeSH descriptors whose meaning is more specific than "Drug Repositioning".
This graph shows the total number of publications written about "Drug Repositioning" by people in this website by year, and whether "Drug Repositioning" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 2 | 2 |
| 2017 | 3 | 11 | 14 |
| 2018 | 6 | 12 | 18 |
| 2019 | 2 | 4 | 6 |
| 2020 | 71 | 67 | 138 |
| 2021 | 28 | 48 | 76 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Repositioning" by people in Profiles.
-
Modulating the host immune response to fight against COVID-19: Where are we in 2021? Virulence. 2021 12; 12(1):1732-1736.
-
Is carbonic anhydrase inhibition useful as a complementary therapy of Covid-19 infection? J Enzyme Inhib Med Chem. 2021 Dec; 36(1):1230-1235.
-
Recent omics-based computational methods for COVID-19 drug discovery and repurposing. Brief Bioinform. 2021 11 05; 22(6).
-
DeepR2cov: deep representation learning on heterogeneous drug networks to discover anti-inflammatory agents for COVID-19. Brief Bioinform. 2021 11 05; 22(6).
-
A transferable deep learning approach to fast screen potential antiviral drugs against SARS-CoV-2. Brief Bioinform. 2021 11 05; 22(6).
-
Drug Repurposing for the SARS-CoV-2 Papain-Like Protease. ChemMedChem. 2022 01 05; 17(1):e202100455.
-
Repurposing pharmaceutical excipients as an antiviral agent against SARS-CoV-2. J Biomater Sci Polym Ed. 2022 01; 33(1):110-136.
-
Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19. Proc Natl Acad Sci U S A. 2021 09 07; 118(36).
-
Re: "Letter to the Editor: Repurposing of an Antisepsis Drug in COVID-19 Patients," by Kumar et al. Assay Drug Dev Technol. 2021 10; 19(7):408-409.
-
Repurposing of a clinically used anti-HPV agent to prevent and treat SARS-CoV-2 infection as an intranasal formulation. Signal Transduct Target Ther. 2021 08 26; 6(1):318.